Jane Rhodes, a neuroscientist with 25 years’ experience in the biotech industry, has been appointed chief executive officer of AstronauTx Ltd, a developer of novel treatments for Alzheimer's disease and other neurodegenerative disorders. Dr Rhodes was previously president and chief business officer at Verge Genomics and has held leadership roles in R&D, corporate strategy, innovation and business development at Biogen and Forma Therapeutics. She holds a PhD in neurophysiology from the University of Manchester, UK. AstronauTx also appointed Magnus Ivarsson, a drug developer with more than 20 years of experience in the pharmaceutical and biotechnology industry, as chief translation and early development officer. In 2023, AstronauTx completed a £48 million Series A financing, announced a partnership with Saniona, a Danish biotechnology company and was awarded an Innovate UK grant to fund preclinical work.
AstronauTx announced the appointment on 2 October 2024.
Copyright 2024 Evernow Publishing Ltd.